Riboflavin prophylaxis in pediatric and adolescent migraine

Maria Condó, Annio Posar, Annalisa Arbizzani, Antonia Parmeggiani

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Migraine is a common disorder in childhood and adolescence. Studies on adults show the effectiveness and tolerability of riboflavin in migraine prevention, while data on children are scarce. This retrospective study reports on our experience of using riboflavin for migraine prophylaxis in 41 pediatric and adolescent patients, who received 200 or 400 mg/day single oral dose of riboflavin for 3, 4 or 6 months. Attack frequency and intensity decreased (P <0.01) during treatment, and these results were confirmed during the follow-up. A large number of patients (77.1%) reported that abortive drugs were effective for controlling ictal events. During the follow-up, 68.4% of cases had a 50% or greater reduction in frequency of attacks and 21.0% in intensity. Two patients had vomiting and increased appetite, respectively, most likely for causes unrelated to the use of riboflavin. In conclusion, riboflavin seems to be a well-tolerated, effective, and low-cost prophylactic treatment in children and adolescents suffering from migraine.

Original languageEnglish
Pages (from-to)361-365
Number of pages5
JournalJournal of Headache and Pain
Volume10
Issue number5
DOIs
Publication statusPublished - 2009

Fingerprint

Riboflavin
Migraine Disorders
Pediatrics
Appetite
Health Care Costs
Vomiting
Retrospective Studies
Stroke
Pharmaceutical Preparations

Keywords

  • Adolescence
  • Childhood
  • Headache
  • Migraine
  • Riboflavin
  • Treatment

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Clinical Neurology

Cite this

Riboflavin prophylaxis in pediatric and adolescent migraine. / Condó, Maria; Posar, Annio; Arbizzani, Annalisa; Parmeggiani, Antonia.

In: Journal of Headache and Pain, Vol. 10, No. 5, 2009, p. 361-365.

Research output: Contribution to journalArticle

Condó, Maria ; Posar, Annio ; Arbizzani, Annalisa ; Parmeggiani, Antonia. / Riboflavin prophylaxis in pediatric and adolescent migraine. In: Journal of Headache and Pain. 2009 ; Vol. 10, No. 5. pp. 361-365.
@article{03254dcf84164d69aac3791efbd8fc9b,
title = "Riboflavin prophylaxis in pediatric and adolescent migraine",
abstract = "Migraine is a common disorder in childhood and adolescence. Studies on adults show the effectiveness and tolerability of riboflavin in migraine prevention, while data on children are scarce. This retrospective study reports on our experience of using riboflavin for migraine prophylaxis in 41 pediatric and adolescent patients, who received 200 or 400 mg/day single oral dose of riboflavin for 3, 4 or 6 months. Attack frequency and intensity decreased (P <0.01) during treatment, and these results were confirmed during the follow-up. A large number of patients (77.1{\%}) reported that abortive drugs were effective for controlling ictal events. During the follow-up, 68.4{\%} of cases had a 50{\%} or greater reduction in frequency of attacks and 21.0{\%} in intensity. Two patients had vomiting and increased appetite, respectively, most likely for causes unrelated to the use of riboflavin. In conclusion, riboflavin seems to be a well-tolerated, effective, and low-cost prophylactic treatment in children and adolescents suffering from migraine.",
keywords = "Adolescence, Childhood, Headache, Migraine, Riboflavin, Treatment",
author = "Maria Cond{\'o} and Annio Posar and Annalisa Arbizzani and Antonia Parmeggiani",
year = "2009",
doi = "10.1007/s10194-009-0142-2",
language = "English",
volume = "10",
pages = "361--365",
journal = "Journal of Headache and Pain",
issn = "1129-2369",
publisher = "BioMed Central Ltd.",
number = "5",

}

TY - JOUR

T1 - Riboflavin prophylaxis in pediatric and adolescent migraine

AU - Condó, Maria

AU - Posar, Annio

AU - Arbizzani, Annalisa

AU - Parmeggiani, Antonia

PY - 2009

Y1 - 2009

N2 - Migraine is a common disorder in childhood and adolescence. Studies on adults show the effectiveness and tolerability of riboflavin in migraine prevention, while data on children are scarce. This retrospective study reports on our experience of using riboflavin for migraine prophylaxis in 41 pediatric and adolescent patients, who received 200 or 400 mg/day single oral dose of riboflavin for 3, 4 or 6 months. Attack frequency and intensity decreased (P <0.01) during treatment, and these results were confirmed during the follow-up. A large number of patients (77.1%) reported that abortive drugs were effective for controlling ictal events. During the follow-up, 68.4% of cases had a 50% or greater reduction in frequency of attacks and 21.0% in intensity. Two patients had vomiting and increased appetite, respectively, most likely for causes unrelated to the use of riboflavin. In conclusion, riboflavin seems to be a well-tolerated, effective, and low-cost prophylactic treatment in children and adolescents suffering from migraine.

AB - Migraine is a common disorder in childhood and adolescence. Studies on adults show the effectiveness and tolerability of riboflavin in migraine prevention, while data on children are scarce. This retrospective study reports on our experience of using riboflavin for migraine prophylaxis in 41 pediatric and adolescent patients, who received 200 or 400 mg/day single oral dose of riboflavin for 3, 4 or 6 months. Attack frequency and intensity decreased (P <0.01) during treatment, and these results were confirmed during the follow-up. A large number of patients (77.1%) reported that abortive drugs were effective for controlling ictal events. During the follow-up, 68.4% of cases had a 50% or greater reduction in frequency of attacks and 21.0% in intensity. Two patients had vomiting and increased appetite, respectively, most likely for causes unrelated to the use of riboflavin. In conclusion, riboflavin seems to be a well-tolerated, effective, and low-cost prophylactic treatment in children and adolescents suffering from migraine.

KW - Adolescence

KW - Childhood

KW - Headache

KW - Migraine

KW - Riboflavin

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=70349246346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349246346&partnerID=8YFLogxK

U2 - 10.1007/s10194-009-0142-2

DO - 10.1007/s10194-009-0142-2

M3 - Article

VL - 10

SP - 361

EP - 365

JO - Journal of Headache and Pain

JF - Journal of Headache and Pain

SN - 1129-2369

IS - 5

ER -